comparemela.com

Latest Breaking News On - Negative symptoms factor score - Page 1 : comparemela.com

FDA Denies Approval of Roluperidone for Negative Symptoms of Schizophrenia

Roluperidone is an investigational drug intended to specifically block the serotonin receptor subtype, 5-HT2A, as well as the sigma2 and adrenergic-α1A receptors.

Remy luthringerMinerva neurosciencesDrug administrationComplete response letterNew drug applicationNegative syndrome scaleNegative symptoms factor scoreExecutive chairman

Minerva Neurosciences, Inc: Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia

WALTHAM, Mass., Aug. 22, 2022(Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that the

United statesHelen shikRemy luthringerFrederick ahlholmMinerva neurosciencesExchange commissionExchange commission onShik communicationsDrug administrationMinerva neurosciences incNew drug applicationExecutive chairmanChief executiveOpen labelNegative syndrome scaleSocial performance scale

Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia

WALTHAM, Mass., Aug. 22, 2022 Minerva Neurosciences, Inc. , a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today. | August 22, 2022

United statesHelen shikRemy luthringerFrederick ahlholmMinerva neurosciencesExchange commissionShik communicationsDrug administrationMinerva neurosciences incGlobenewswire incNew drug applicationExecutive chairmanChief executiveOpen labelNegative syndrome scaleSocial performance scale

vimarsana © 2020. All Rights Reserved.